Elsaad products
Member Login


Newsletter
 
 
Library of articles
 
Product Studies » Cefixime Studies
Comparison of 5-day and 10-day cefixime in the treatment of acute exacerbation of chronic bronchitis.

Chemotherapy. 2001 Sep;44 Suppl 1:15-8.

Lorenz J.

Source

2nd Medical Department, District Hospital Lüdenscheid, Lüdenscheid, Germany.

Abstract

The focus of a multicenter trial conducted in Germany was to investigate whether a 5-day short course of cefixime 400 mg was equivalent to a 10-day standard therapy of cefixime 400 mg in the treatment of acute exacerbation of chronic bronchitis (AECB).
In the 167 patients who were evaluated, on day 11 following treatment with once-daily oral cefixime resulted in clinical success in 89 and 91% of cases in the 5-day and 10-day treatment groups, respectively.

At days 6, 11 and 30 after treatment there was no statistically significant difference between the 2 dose groups (p < 0.01). Bacteriological equivalence was also demonstrated.

Gastrointestinal adverse events showed a tendency to occur less frequently in the 5-day group, but the difference was not significant.

The results indicate that a short course therapy is equivalent in efficacy to the standard 10-day therapy in patients with AECB, and may thus offer cost advantages.

PMID: 9797418

 
   
 
Powered by: TSS-EST.COM